Lutropin Alfa
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Lutropin Alfa
- Lutropin Alfa: From Fertility Treatment to Postural Orthostatic Tachycardia Syndrome (POTS)
Lutropin Alfa: From Fertility Treatment to Postural Orthostatic Tachycardia Syndrome (POTS)
One-Sentence Summary
Lutropin alfa is a recombinant human luteinizing hormone (LH), known pharmacologically for its role in promoting ovulation and gonadal steroidogenesis via the LHCGR receptor. The TxGNN model predicts it may be effective for Postural Orthostatic Tachycardia Syndrome (POTS), but currently no clinical trials and no publications support this direction — this is a pure knowledge-graph statistical association with no known mechanistic basis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not formally recorded in this dataset. Based on the drug’s known pharmacology (LH receptor agonism), it is used to induce ovulation/steroidogenesis in fertility treatment |
| Predicted New Indication | Postural Orthostatic Tachycardia Syndrome (POTS) |
| TxGNN Prediction Score | 97.04% |
| Evidence Level | L5 (model prediction only) |
| EU/TW Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for Lutropin alfa is not available in this evidence pack (flagged as a High-severity data gap, DG002). Based on information embedded in the evidence rationale, Lutropin alfa is a recombinant human luteinizing hormone (LH) that acts on LHCGR receptors in ovarian granulosa cells and testicular Leydig cells, promoting ovulation and steroidogenesis — a peripheral, gonad-restricted endocrine mechanism.
POTS, in contrast, is primarily a disorder of autonomic nervous system regulation and cardiovascular autonomic reflexes. The evidence pack’s own mechanistic assessment explicitly states there is no known direct link between LH/LHCGR signaling and autonomic/cardiovascular regulation — the connection identified by TxGNN is an indirect graph-based association rather than a biologically validated pathway. This candidate should therefore be treated as a low-confidence, exploratory signal rather than a mechanistically grounded repurposing hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
EU Market Information
No marketing authorization exists for Lutropin alfa in the current dataset — market status is recorded as Not Marketed, with 0 total licenses on file.
Safety Considerations
Please refer to the SmPC for safety information.
(Note: TFDA label warnings/contraindications are flagged as a Blocking data gap (DG001) — this must be resolved before any safety review can proceed to Stage 1.)
Conclusion and Next Steps
Decision: Hold
Rationale:
- No clinical trials or literature evidence exist for the POTS candidate, and the mechanistic rationale explicitly acknowledges no known biological link between LH signaling and autonomic/cardiovascular regulation — this is an L5, S0-stage signal (model prediction only).
To proceed, the following is needed:
- TFDA label PDF (warnings/contraindications) — Blocking, required before any safety pre-screen (S1) can occur
- DrugBank MOA data confirmation — needed to properly assess mechanistic plausibility
- Independent mechanistic or preclinical evidence linking gonadotropin signaling to autonomic nervous system function, before considering further investment in this candidate
- If pursuing endocrine-related candidates instead, note that rank #9 (multiple endocrine neoplasia) has one Phase 4 clinical trial (NCT01081626, L3/S1, “Research Question”) that warrants manual verification of trial design/relevance before further action
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.